CliffBio
small molecule

COMETRIQ

CABOZANTINIB S-MALATE

Loss of exclusivityFebruary 2032latest FDA-listed patent expiry
CompanyExelixis →See this company's full patent-cliff portfolio

Drug detail

Brand nameCOMETRIQ
Active ingredientCABOZANTINIB S-MALATE
StrengthEQ 80MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2012
Marketing statusRX

Listed patents

PatentExpiresType
11298349February 2032product
12128039February 2032product
9717720February 2032product
8877776October 2030substance, product
11091440January 2030product
11098015January 2030use U-1617
11091439January 2030substance
7579473August 2026substance, product

More from Exelixis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.